CA3256744A1 - IRREVERSIBLE MUTEGFR INHIBITORS - Google Patents
IRREVERSIBLE MUTEGFR INHIBITORSInfo
- Publication number
- CA3256744A1 CA3256744A1 CA3256744A CA3256744A CA3256744A1 CA 3256744 A1 CA3256744 A1 CA 3256744A1 CA 3256744 A CA3256744 A CA 3256744A CA 3256744 A CA3256744 A CA 3256744A CA 3256744 A1 CA3256744 A1 CA 3256744A1
- Authority
- CA
- Canada
- Prior art keywords
- pyridin
- pyrazin
- dihydropyrazolo
- methyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338419P | 2022-05-04 | 2022-05-04 | |
| US63/338,419 | 2022-05-04 | ||
| PCT/EP2023/061672 WO2023213882A1 (en) | 2022-05-04 | 2023-05-03 | Irreversible mutegfr inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3256744A1 true CA3256744A1 (en) | 2023-11-09 |
Family
ID=86426125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3256744A Pending CA3256744A1 (en) | 2022-05-04 | 2023-05-03 | IRREVERSIBLE MUTEGFR INHIBITORS |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP4519265A1 (de) |
| CA (1) | CA3256744A1 (de) |
| WO (1) | WO2023213882A1 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025093588A1 (en) * | 2023-11-03 | 2025-05-08 | Bayer Aktiengesellschaft | Pyrazolopiperazine compounds |
| WO2025235872A1 (en) * | 2024-05-10 | 2025-11-13 | Schrödinger, Inc. | Heterocyclics as egfr inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966781A (en) | 1970-12-17 | 1976-06-29 | Merck Sharp & Dohme (I.A.) Corporation | Deuteration of functional group-containing hydrocarbons |
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| US8791162B2 (en) | 2011-02-14 | 2014-07-29 | Merck Sharp & Dohme Corp. | Cathepsin cysteine protease inhibitors |
| TWI702205B (zh) | 2017-10-06 | 2020-08-21 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 表皮生長因子受體抑制劑 |
| EP3700904B1 (de) | 2017-10-24 | 2023-07-19 | Bayer AG | 4h-pyrrolo[3,2-c]pyridin-4-on derivate |
| WO2019233459A1 (zh) | 2018-06-08 | 2019-12-12 | 江苏威凯尔医药科技有限公司 | 人表皮生长因子受体抑制剂及其制备方法和应用 |
| WO2020001350A1 (zh) | 2018-06-27 | 2020-01-02 | 江苏威凯尔医药科技有限公司 | Egfr抑制剂及其制备和应用 |
| WO2020001351A1 (zh) | 2018-06-27 | 2020-01-02 | 江苏威凯尔医药科技有限公司 | Egfr抑制剂及其制备和应用 |
| CN110698461B (zh) | 2018-07-09 | 2024-04-05 | 上海翰森生物医药科技有限公司 | 第三代egfr抑制剂的制备方法 |
| CN110857292A (zh) | 2018-08-22 | 2020-03-03 | 上海艾力斯医药科技有限公司 | 一种egfr激酶抑制剂及其制备方法和应用 |
| CN113056272A (zh) | 2018-09-21 | 2021-06-29 | 光谱医药公司 | 新的喹唑啉egfr抑制剂 |
| CN110407852A (zh) | 2019-08-27 | 2019-11-05 | 药雅科技(上海)有限公司 | 一种噻吩并嘧啶双芳香环衍生物表皮生长因子抑制剂及其制备方法与用途 |
| CN110357863B (zh) | 2019-08-27 | 2023-04-14 | 药雅科技(上海)有限公司 | 一种三嗪双芳香环衍生物表皮生长因子抑制剂及其制备方法与用途 |
-
2023
- 2023-05-03 CA CA3256744A patent/CA3256744A1/en active Pending
- 2023-05-03 WO PCT/EP2023/061672 patent/WO2023213882A1/en not_active Ceased
- 2023-05-03 EP EP23725134.3A patent/EP4519265A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4519265A1 (de) | 2025-03-12 |
| WO2023213882A1 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020262221B2 (en) | 4H-pyrrolo(3,2-c)pyridin-4-one compounds | |
| US11339157B1 (en) | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | |
| CN114945571B (zh) | 环状化合物及其使用方法 | |
| US12403135B2 (en) | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives | |
| US20240307362A1 (en) | 4H-PYRROLO[3,2-c]PYRIDIN-4-ONE COMPOUNDS | |
| US20230064983A1 (en) | 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer | |
| CA3201333A1 (en) | N-[2-({4-[3-(anilino)-4-oxo-4,5,6,7-tetrahydro-1h-pyrrolo[3,2-c]pyridin-2-yl]pyridin-3-yl)oxy)ethyl]prop-2-enamide derivatives and similar compounds as egfr inhibitors for the treatment of cancer | |
| WO2022023340A1 (en) | Substituted heterocyclic compounds and therapeutic uses thereof | |
| EP4188929A1 (de) | Substituierte pyrrolopyridinonderivate und therapeutische verwendungen davon | |
| CA3256744A1 (en) | IRREVERSIBLE MUTEGFR INHIBITORS | |
| WO2024028316A1 (en) | 1h-pyrrolo[3,2-b]pyridine derivatives as irreversible inhibitors of mutant egfr for the treatment of cancer | |
| WO2025093588A1 (en) | Pyrazolopiperazine compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20241101 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250221 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250222 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250222 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250224 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250425 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250425 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260421 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260423 |